Intrinsic mechanism and pharmacologic treatments of noise-induced hearing loss

• Published in: Theranostics Vol. 13; no. 11; pp. 3524 - 3549
• Main Authors: Xu, Ke, Xu, Baoying, Gu, Jiayi, Wang, Xueling, Yu, Dehong, Chen, Yu
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2023; Ivyspring International Publisher
• Subjects: Alzheimer's disease; Cochlear implants; Drug Delivery Systems; Drug therapy; Ear, Inner; Eardrum; Hair; Hearing loss; Hearing Loss, Noise-Induced - drug therapy; Hearing Loss, Noise-Induced - genetics; Hearing protection; Homeostasis; Humans; Morphology; Neurotoxicity; Noise control; Pathogenesis; Review; Sound waves; drug delivery systems; noise-induced hearing loss; nanoparticles; pharmacologic strategies
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.83383

Noise accounts for one-third of hearing loss worldwide. Regretfully, noise-induced hearing loss (NIHL) is deemed to be irreversible due to the elusive pathogenic mechanisms that have not been fully elucidated. The complex interaction between genetic and environmental factors, which influences numerous downstream molecular and cellular events, contributes to the NIHL. In clinical settings, there are no effective therapeutic drugs other than steroids, which are the only treatment option for patients with NIHL. Therefore, the need for treatment of NIHL that is currently unmet, along with recent progress in our understanding of the underlying regulatory mechanisms, has led to a lot of new literatures focusing on this therapeutic field. The emergence of novel technologies that modify local drug delivery to the inner ear has led to the development of promising therapeutic approaches, which are currently under clinical investigation. In this comprehensive review, we focus on outlining and analyzing the basics and potential therapeutics of NIHL, as well as the application of biomaterials and nanomedicines in inner ear drug delivery. The objective of this review is to provide an incentive for NIHL's fundamental research and future clinical translation.